The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim

Molecular Cancer Therapeutics

Volumn 4, Issue 3, 2005, Pages 443-449

  Nikrad, Malti ^a,c   Johnson, Thomas ^a,d   Puthalalath, Hamsa ^b   Coultas, Leigh ^b   Adams, Jerry ^b   Kraft, Andrew S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BH3 PROTEIN; BIM PROTEIN; BORTEZOMIB; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG PROTEIN BINDING; EMBRYO; FIBROBLAST; GENE DISRUPTION; HUMAN; HUMAN CELL; HYPOTHESIS; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BORONIC ACIDS; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FIBROBLASTS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPRECIPITATION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; PEPTIDE FRAGMENTS; PLASMIDS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15944387964     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-9.
2. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009-15.
3. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
4. Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
5. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-9.
6. Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase-9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22:4953-63.
7. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10.
8. Cory S, Huang D, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
9. Willams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003;63:7338-44.
10. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
11. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
12. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002;9:505-12.
13. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003;17:2481-95.
14. Bouillet P, Cory S, Zhang LC, Strasser A, Adams JM. Degenerative disorders caused by Bcl-2-deficieny prevented by loss of its BH3 antagonist Bim. Dev Cell 2001;1:645-53.
15. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-8.
16. Coultas L, Bouillet P, Stanley EG, et al. Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol 2004;24: 1570-81.
17. Hur J, Chesnes J, Coser KR, et al. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed cancer cells and provokes apoptosis. Proc Natl Acad Sci U S A 2004;101:2351-56.
18. Arena V, Martini M, Luongo M, Capelli A, Larocca LM. Mutations of the BlK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer 2003;38:91-6.
19. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-3.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
21. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa (NJ): Humana Press; 2000. p. 365-86. Source code available at http://frodo.wi.mit.edu/primer3/primer3_code.html.
22. Glantz SA. Primer of biostatistics. New York: McGraw-Hill Book Co; 1981.
23. Sun L, Chen ZJ. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 2004;16:119-26.
24. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK 1/2 pathway promotes phosphorylation and the proteasome dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003;278: 18811-6.
25. Akiyama T, Bouillet P, Miyazaki T, et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family members. EMBO J 2003;22:6653-64.
26. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998:17:384-95.
27. Naumann U, Schmidt F, Wick W, et al. Adenoviral natural born killer gene therapy for malignant glioma. Hum Gene Ther 2003;14:12325-46.
28. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol 1996;16:5857-64.
29. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-67.
30. Danial NN, Gramm CF, Scoranno L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003;424:952-6.
31. Zinkel SS, Ong CC, Ferguson DO, et al. Proapoptotic Bid is required for myeloid homeostasis and tumor suppression. Genes Dev 2003;17: 229-39.
32. Villunger A, Michelak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
33. Iglesias-Serret D, Pique M, Gil J, Pons G, Lopez JM. Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 2003;417:141-52.
34. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2:183-92.
35. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14:2060-71.
36. Marshanski V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130-42.
37. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-82.
38. Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent cJun degradation in vivo is mediated by the delta domain. Cell 1994;78:787-98.
39. Verma S, Budarf ML, Emanuel BS, Chinnadurai G. Structural analysis of the human pro-apoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences. Gene 2000;254: 157-62.